Background {#Sec1}
==========

Tuberculosis (TB) remains a major global health problem and ranks as the leading cause of death from an infectious disease worldwide. In 2017, TB infected about 10.0 million people and approximately 16% (1.6 million) of infected patients died from the disease, which was a higher global total for new TB cases and deaths than previous one. Of the 1.6 million died cases, 300,000 occurred among people infected with human immunodeficiency virus (HIV) \[[@CR1]\].

Drug-resistant TB, including multidrug-resistant TB (MDR-TB, defined as resistance to at least isoniazid and rifampicin, the two most important first-line anti-TB drugs) and extensively drug-resistant TB (XDR-TB, defined as MDR-TB plus resistance to any fluoroquinolone, such as ofloxacin or moxifloxacin, and to at least one of three injectable second-line drugs, amikacin, capreomycin, or kanamycin) has become a serious threat to global health \[[@CR2]\]. In 2017, approximately 460,000 people, which means 3.5% of new and 18% of previously treated TB cases, were estimated to have had MDR-TB globally. And 9.0% of them had developed to XDR-TB. Rifampicin resistance (RR) was the most common resistance drug, affected approximately 558,000 people \[[@CR1]\].

When TB is detected and effectively treated, the disease is largely curable. However, accurate and rapid detection of TB can be difficult, as challenging sample collection from deep-seated tissues and the paucibacillary characteristics of the disease \[[@CR3]\]. Worldwide, approximately 35% of all forms of TB and 75% of patients with MDR-TB remain undiagnosed \[[@CR4]\]. Notablely, under 3% of people who diagnosed with TB are tested to have certain pattern of drug resistance \[[@CR5]\]. Xpert MTB/RIF was an effective, rapid, new method to diagnose TB and RR-TB, which was recommended by WHO \[[@CR1]\].

Traditionally, the best available reference standard for TB diagnosis is solid and/or liquid culture. However, in clinical practice, prolonged turnaround times and limited laboratory infrastructure in resource-limited settings undermine the utility of culture-based diagnosis \[[@CR6]\]. Histology is widely used for the diagnosis of TB where the technical pathologists are available However, it is time-consuming, technically demanding, and lacks specificity \[[@CR7]\]. In early 2011, the World Health Organization (WHO) endorsed the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, USA) \[[@CR8]\], a novel, rapid, automated, cartridge-based nucleic acid amplification test (NAAT), for the initial diagnosis in patients with suspected pulmonary MDR-TB or HIV-associated pulmonary TB \[[@CR9], [@CR10]\]. It can simultaneously detect TB through detection of the DNA of *Mycobacterium tuberculosis* and simultaneously identify a majority of the mutations that confer rifampicin resistance (which is highly predictive of MDR-TB). A high accuracy for pulmonary TB detection (sensitivity 89%, specificity 99%) was obtained \[[@CR11]\]. In late 2013, WHO expanded its recommendations to include the diagnosis of TB in children and some forms of extrapulmonary TB (EPTB) \[[@CR1]\].

A series of meta-analyses were carried out to determine the diagnostic accuracy of Xpert MTB/RIF in different forms of TB \[[@CR12]--[@CR14]\], however, evaluation of its accuracy in rifampicin resistance is rare \[[@CR11]\]. More importantly, no study estimated the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance in countries with different TB prevalence and income till now. To replenish this, in this review, we synthesized the available data, taking into account the accuracy of Xpert MTB/RIF in diagnosing rifampicin resistance.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

We searched the MEDLINE, Cochrane library, EMBASE, and Web of Knowledge for published works without language restrictions. The key searching words were used were: "Xpert MTB/RIF", "Xpert", "Gene Xpert", plus "rifampicin resistance". Our last search was accomplished on March 3, 2019.

Study selection and data extraction {#Sec4}
-----------------------------------

The study selection and data extraction procedures were performed by two researchers (Kaican Zong and Hui Zhou) independently. Any differences in the process were solved by discussing with a third author (Shiying Li).

### Inclusion criteria and exclusion criteria {#Sec5}

Studies included in our meta-analysis should meet the following criteria: (i) clinical trials that used Xpert MTB/RIF for the detection of rifampicin resistance; (ii) samples were body tissues or fluid from suspected TB patients; (iii) the number of cases were more than 10; (iv) original data were sufficient to calculate the true positive (TP), true negative (TN), false positive (FP), and false negative (FN); (v) drug-susceptibility testing (DST) was used as the gold standard. Studies were excluded from our meta-analysis if they were: (i) case report; (ii) abstract of any conference; (iii) non-clinical research; (iv) review.

### Data extraction {#Sec6}

The following data were extracted from each included study: first author, year of publication, country, study settings, gender, the number of patients, the number and type of samples, diagnostic characteristics of Xpert MTB/RIF such as TP, TN, FP and FN. We sent e-mails to the authors for more details when data of individual studies were insufficient for a meta-analysis. In the case of inability to obtain data from the authors, the studies were excluded.

Statistical analysis {#Sec7}
--------------------

MIDAS modules in the STATA statistical software (version 12.0; STATA Corporation, College Station, TX, USA) was used to perform the meta-analyses. The summary receiver operating characteristic (SROC) model and the bivariate random-effects model were used in our study to evaluate the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance detection. For each study, we calculated the sensitivity and specificity of Xpert MTB/RIF to diagnose rifampicin resistance along with 95% confidence intervals.

Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was introduced to assess the quality of each included study. The Review Manager software (version 5.3, The Nordic Cochrane Centre, Copenhagen, Denmark) was used to present the result of QUADAS assessment.

We assessed the heterogeneity between included studies by using a bivariate boxplot, which can describe the degree of interdependence including the central location and identification of any outliers with an inner oval representing the median distribution of the data points and an outer oval representing the 95% confidence bound (by visually examining the position of each individual study, within the range of boxplot suggesting more heterogeneity).

Results {#Sec8}
=======

Description of included studies {#Sec9}
-------------------------------

Finally, we included 97 studies in this meta-analysis \[[@CR15]--[@CR111]\] (Fig. [1](#Fig1){ref-type="fig"}), including 26,037 samples for the diagnosis of rifampicin resistance. All studies were in English except five (three in Chinese \[[@CR46], [@CR64], [@CR111]\] and two in Turkish \[[@CR31], [@CR79]\]). Twenty-six studies (26.8%) were conducted in high income countries (the World Bank income classification 2018) and 52 studies (53.6%) were in the 22 countries with a high burden of TB \[[@CR1]\].Fig. 1Flow diagram for literature search and selections of studies in this meta-analysis

The median number of samples per study was 268 for rifampicin resistance detection. The samples of 56 included studies were pulmonary, such as sputum and BAL. Another 15 studies were extrapulmonary samples (e.g. body fluid, FNA, stool and blood), 16 studies included samples of both pulmonary and extrapulmonary (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Characteristics of studies included in the meta-analysis for rifampicin-resistance tuberculosis detectionStudyFirst author \[ref.\]YearCountryStudy settingMale (%)HIV (%)Age (year) (Median, IQR)Patient selecting methodTotal samples n (included n)Specimen type (samples n)Gold standard1Al-Ateah SM \[[@CR15]\]2012Saudi ArabiaLaboratory126 (53.8)1 (0.4)NRCross-sectional Unspecified234 (239)Sputum (56), BAL (116); tissue (16), CSF (14), FNA (5), body fluid (22), abscess (10)DST2Antonenka U \[[@CR16]\]2013GermanClinicalNRNRNRRetrospective Unspecified121 (121)Respiratory specimens (121)Solid or liquid media DST3Balcells ME \[[@CR17]\]2012ChileClinical127 (79.4)160 (100)Adults\> 18 (37.4, 19--65)Cross-sectional Prospective Consecutive160 (12)Sputum (160)Solid and liquid media DST4Barmankulova A \[[@CR18]\]2015KyrgyzstanLaboratory172 (57.3)NRMedian 34, IQR 25--45Cross-sectional Unspecified300 (191)Sputum (300)Solid and liquid media DST5Barnard M \[[@CR19]\]2012South AfricaLaboratoryNRNRNRUnspecified Consecutive282 (68)Sputum (282)DST6Bates M \[[@CR20]\]2013ZambiaClinicalNR22 (2.4)Children≤15Prospective Unspecified930 (930)Sputum, gastric lavage aspirate (930)Liquid culture7Biadglegne F \[[@CR21]\]2014EthiopiaClinical99 (42.9)NR14.7% ≤ 14, 85.3% \> 14Cross-sectional Unspecified231 (32)Lymph node aspirates (231)DST8Blakemore R \[[@CR22]\]2010AmericaClinicalNRNRNRUnspecified Unspecified168 (79)Sputum (168)DST9Boehme CC \[[@CR23]\]2010Clinical929 (53.7)392 (22.7)Adults≥18 (34, 17--88)Prospective Consecutive1730 (720)Sputum (1730)Solid media DSTPeru181 (53.1)3 (0.9)Adults≥18 (31, 18--79)341 (209)Sputum (341)Solid media DSTAzerbaijan251 (71.1)9 (2.6)Adults≥18 (37, 20--69)353 (143)Sputum (353)Solid or liquid media DSTSouth Africa357 (49.2)376 (51.8)Adults≥18 (34, 18--74)726 (183)Sputum (726)Liquid media DSTIndia140 (45.2)4 (12.9)Adults≥18 (30, 17--88)310 (185)Sputum (310)Liquid media DST10Boehme CC \[[@CR24]\]2011Clinical4043 (60.8)1255 (18.9)Adults≥18 (38, 29--50)Unspecified Consecutive6648 (1060)Sputum (6648)DSTPeru607 (51.2)5 (0.4)Adults≥18 (37, 26--53)1185 (185)Sputum (1185)Liquid media DSTAzerbaijan748 (99.9)1 (0.1)Adults≥18 (36, 30--44)749 (211)Sputum (749)Liquid media DSTSouth Africa1275 (50.6)947 (37.5)Adults≥18 (36, 29--46)2522 (188)Sputum (2522)Solid media DSTUganda202 (54.3)254 (68.3)Adults≥18 (32, 26--38)372 (116)Sputum (372)Solid media DSTIndia628 (69.6)40 (4.4)Adults≥18 (45, 32--58)902 (103)Sputum (902)Solid media DSTPhilippines583 (63.5)8 (0.9)Adults≥18 (47, 34--58)918 (257)Sputum (918)DST11Bowles EC \[[@CR25]\]2011NetherlandsClinicalNRNRNRUnspecified Unspecified89 (60)Sputum (86), pleural fluid (1), gastric fluid (1), bronchial washing (1)DST12Carriquiry G \[[@CR26]\]2012PeruClinical95 (73)131 (100)Adults≥18 (35, 29--42)Cross-sectional Unspecified131 (39)Sputum (131)Solid and liquid media DST13Cayci YT \[[@CR27]\]2017TurkeyLaboratoryNRNRNRUnspecified Unspecified34 (34)Respiratory (19) and Non-respirator specimens (15)Liquid media DST14Chakravorty S \[[@CR28]\]2017South, Africa, IndiaLaboratoryNRNRNRProspective Unspecified139 (139)Sputum (139)Liquid media DST15Chiang TY \[[@CR29]\]2018ChinaClinical876 (29.6)NRMedian 55, IQR 35.8--70.0Prospective Unspecified2957 (697)Sputum (697)Solid and liquid culture16Chikaonda T \[[@CR30]\]2017MalawiClinicalNR200 (57.0)Adult≥18Retrospective Random351 (188)Sputum (60)Solid and liquid media DST17Ciftçi IH \[[@CR31]\]2011TurkeyClinicalNRNRNRUnspecified Unspecified85 (24)Sputum (50), BAL (25), thorasynthesis fluid (5), urine (5)Liquid media DST18Deggim V \[[@CR32]\]2013SwitzerlandClinicalNRNRNRProspective Unspecified79 (10)Respiratory and Non-respirator specimens (79)DST19Dharan NJ \[[@CR33]\]2016Russia, Peru, Hong Kong, Haiti, USAClinical358 (65.8)536 (98.5)Median 54.2, IQR 19--88Unspecified, Unspecified544 (185)Sputum (185)DST20Dorman SE \[[@CR34]\]2012South AfricaLaboratory6469 (93.8)602 (8.7)Median 43, IQR 34--49Cross-sectional Consecutive6893 (144)Sputum (6893)Liquid media DST21Dorman SE \[[@CR35]\]2018South Africa, Uganda, Kenya, India, China, Georgia, Belarus, BrazilClinical1059 (60.4)441 (25.2)Median 38, IQR 28--50Prospective Unspecified1753 (551)Sputum (551)Liquid media DST22Du J \[362015ChinaClinical70 (55.6)5 (4.0)Adults\> 16 (38.6, 25.4--51.8)Unspecified Unspecified126 (126)Pleural biopsy (126), pleural fluid specimens (126)Liquid media DST23Feliciano CS \[[@CR37]\]2018Brazil, MozambiqueClinical22 (75.9)6 (20.7)NRCross-sectional Unspecified29 (29)NR (29)Solid media DST24Giang do C \[[@CR38]\]2015VietnamClinical98 (65.3)0 (0)Children\< 15 (18.5 months, 5--170 months)Prospective Consecutive150 (29)Sputum (79), Gastric fluid (215), CSF (3), Pleural fluid (4), Cervical lymphadenopathic pus (1)Liquid media DST25Gu Y \[[@CR39]\]2015ChinaClinical28 (46.7)NRMedian 39.7, IQR 19.5--74.6Prospective Unspecified60 (24)Pus specimens (60)Liquid media DST26Guenaoui K \[[@CR40]\]2016FranceLaboratory35 (0.7)NRNRProspective Unspecified50 (50)Sputum (50)Liquid DST27Helb D \[[@CR41]\]2010UgandaClinical38 (59.3)20 (31.3)Median 34, IQR 18--60Retrospective Consecutive64 (64)Sputum (64)DST28Hillemann D \[[@CR42]\]2011GermanLaboratoryNRNRNRUnspecified Consecutive521 (29)Urine (91), gastric aspirate (30), tissue (245), pleural fluid (113), CSF (19), stool (23)Liquid media DST29Huang H \[[@CR43]\]2018ChinaLaboratoryNRNRNRRetrospective Unspecified2910 (1066)NRLiquid media DST30Huh HJ \[[@CR44]\]2014South KoreaClinical197 (65.7)1 (0.3)Median 58, IQR 18--93Retrospective Unspecified300 (98)Sputum (264), Bronchial washing or BAL (39)Solid and liquid media DST31Hu P \[[@CR45]\]2014ChinaLaboratory1037 (76.7)NR3.2% \< 20, 96.8% ≥ 20Unspecified Consecutive1352 (332)Sputum (1352)Solid media DST32Jin YH \[[@CR46]\]2017ChinaClinical59 (54.1)NRMedian 48.6, IQR 24.0--73.1Unspecified Unspecified109 (48)Pus (48)Liquid media DST33Kawkitinarong K \[[@CR47]\]2017ThailandClinical284 (58.6)128 (25.9)Median 41, IQR 30.8--54.3Prospective Unspecified521 (228)Pulmonary specimens (228)DST34Khalil KF \[[@CR48]\]2015PakistanClinical36 (38.7)0 (0)\> 16, 19.5--57.6Unspecified Consecutive93 (93)BAL (93)Solid media DST35Kim CH \[[@CR49]\]2014South KoreaClinical104 (60.8)1 (0.6)Median 58.6, IQR 41.02--76.18Retrospective Unspecified171 (26)Pulmonary (160), Non-pulmonary (38) specimensSolid media DST36Kim CH \[[@CR50]\]2015South KoreaClinical217 (56.7)1 (0.3)Median 56.31, IQR 38.43--74.18Retrospective Convenience383 (444)Sputum (176), Bronchial washes (225), BAL (4); Pleural fluid (36), Tissue (1), Pericardial fluid (1), Lymph node (1)Solid media DST37Kim MJ \[[@CR51]\]2015South KoreaLaboratoryNRNRNRUnspecified Convenience52 (45)Sputum (36), bronchial washing (10), pleural fluid (3), pleural mass (1), urine (2)Liquid media DST38Kim SY \[[@CR52]\]2012South KoreaClinicalNRNRNRUnspecified Consecutive71 (62)Sputum (71)Solid and liquid DST39Kim YW \[[@CR53]\]2015South KoreaClinical761 (53.3)12 (0.8)Median 59, IQR 0--99Retrospective Consecutive1429 (1540)LN and tissue/pus (397), body fluid (469), CSF (254), joint fluid (283), urine (106), others (31)Solid media DST40Kim YW \[[@CR54]\]2015South KoreaClinical196 (61.1)NRMedian 56, IQR 38--71Retrospective Consecutive321 (321)Sputum (321)DST41Kokuto H \[[@CR55]\]2015JapanClinical51 (54.8)0 (0)Adult≥20 (59.6, 45.0--75.0)Retrospective Convenience93 (56)fecal specimens (93)DST42Kostera J \[[@CR56]\]2018BangladeshClinicalNRNRNRUnspecified Unspecified132 (122)Sputum (122)Liquid media DST43Kurbaniyazova G \[[@CR57]\]2017KyrgyzstanLaboratoryNRNRAdult≥18Retrospective Unspecified2734 (364) (414)NRSolid and liquid media DST44Kurbatova EV \[[@CR58]\]2013RussiaClinicalNRNRAdults≥18Unspecified Consecutive201 (99)Sputum (201)Solid and liquid media DST45Kwak N \[[@CR59]\]2013South KoreaClinical426 (62.5)5 (0.7)Median 61, IQR 47.5--73.0Retrospective Unspecified681 (127)Sputum (127)Solid media DST46Lawn SD \[[@CR60]\]2011South AfricaClinical162 (34.6)468 (100)Adults≥18 (33.6, 27.8--40.7)Prospective Consecutive468 (55)Sputum (468)Liquid media DST47Lee HY \[[@CR61]\]2013South KoreaClinical78 (59.1)1 (0.8)Median 54.0, IQR 18--90Retrospective Unspecified132 (132)Bronchoscopy specimens (132)Ogawa media DST48Li Q \[[@CR62]\]2016ChinaLaboratoryNRNRNRUnspecified Consecutive1973 (449)Sputum (449)Liquid media DST49Li Y \[[@CR63]\]2017ChinaLaboratory251 (60.6)NRMedian 48.5, IQR 38.3--58.7Unspecified Consecutive420 (59)Extra-pulmonary specimens (59)Solid media DST50Liu X \[[@CR64]\]2015ChinaClinicalNRNRNRUnspecified Unspecified134 (44)Pleural biopsy and pleural fluid specimens (100)Liquid media DST51Lorent N \[[@CR65]\]2015CambodiaClinical160 (53.5)189 (64.5)Median 43, IQR 34--52Prospective Consecutive299 (102)Sputum (102)Solid media DST52Luetkemeyer AF \[[@CR66]\]2016USA South Africa BrazilLaboratory446 (45.0)617 (62.2)Median 46, IQR 35--64Unspecified Unspecified992 (194)Sputum (2)DST53Metcalfe JZ \[[@CR67]\]2016ZimbabweClinical216 (61.4)238 (67.6)Median 36.3, IQR 29.0--44.4Prospective Consecutive352 (161)Sputum (161)Solid and liquid media DST54Mokaddas E \[[@CR68]\]2015KuwaitLaboratoryNRNRNRUnspecified Unspecified452 (452)Sputum (287), FNA (66), pus (58), pleural fluid (14), tissue (10), other sterile fluids (8), urine (5), CSF (2), stool (2).Liquid media DST55Moon HW \[[@CR69]\]2015South KoreaClinicalNRNRNRUnspecified Unspecified100 (100)Respiratory specimens (100)DST56Moure R \[[@CR70]\]2011SpainClinicalNRNRNRRetrospective Unspecified122 (85)Sputum (92), BA (12), pulmonary biopsy (1); pleural fluid (4), gastric aspirate (5), urine (2), stool (1),cerebrospinal fluid (3), ascitic fluid (2), lymph node aspirate (1), skin biopsy (1), mammary abscess (1)DST57Mwanza W \[[@CR71]\]2018ZambiaLaboratoryNRNRNRUnspecified Consecutive1070 (24)NR (24)Liquid media DST58Myneedu VP \[[@CR72]\]2014IndiaLaboratoryNRNRNRUnspecified Unspecified134 (88)Sputum (134)Liquid media DST59N'guessan K \[[@CR73]\]2014Cote d'IvoireClinical91 (75.8)NRMedian 34.2, IQR 24.1--44.3Unspecified Unspecified120 (29)Sputum (120)Liquid media DST60N'Guessan K \[[@CR74]\]2018Côte d'IvoireClinical715 (65.3)130 (12)Median 33, IQR 18--80Cross-sectional Consecutive1095 (162)Sputum (162)Liquid media DST61Nikolayevskyy V \[[@CR75]\]2018UkraineClinical2393 (68.8)1265 (36.4)Median 38.3, IQR 27--51.6Retrospective Unspecified3478 (3167)Pulmonary specimens (3167)Solid and liquid media DST62Nicol MP \[[@CR76]\]2011South AfricaClinical250 (55.3)108 (23.9)Children≤15 (19.4 months, 11.1--46.2 months)Prospective Consecutive452 (77)Sputum (452)DST63O'Grady J \[[@CR77]\]2012ZambiaClinical446 (50.6)595 (67.5)Adults\> 15 (35, 28--43)Prospective Unspecified881 (96)Sputum (881)Liquid media DST64Ou X \[[@CR78]\]2014ChinaLaboratory1741 (70.9)NRNRUnspecified Consecutive2454 (616)Sputum (2454)Solid media DST65Ozkutuk N \[[@CR79]\]2014TurkeyLaboratoryNRNRNRUnspecified Unspecified2639 (133)Sputum (721), BAL (757), gastric fluid (94), endotracheal aspirates (30), transtracheal aspirate (9); urine (341), pleural fluid (232), tissue (176), CSF (111), abscesses (94), peritoneal fluid (42), pericardial fluid (18), joint fluid (7), other (7)Liquid media DST66Pan X \[[@CR80]\]2018ChinaClinical120 (63.2)NRMedian 46.7, IQR 16--84Prospective Unspecified190 (62)Sputum,BAL (62)DST67Pang Y \[[@CR81]\]2014ChinaClinical128NRChildren\< 14Prospective Consecutive211 (10)Gastric lavage aspirates (211)Liquid media DST68Park KS \[[@CR82]\]2013South KoreaClinicalNRNRNRProspective Consecutive320 (19)Respiratory specimens (320)Liquid media DST69Pimkina E \[[@CR83]\]2015LithuaniaLaboratory559 (70.6)NRAge ≥ 15Retrospective Unspecified791 (264)Respiratory specimens (264)Solid or liquid media DST70Pinyopornpanish K \[[@CR84]\]2015ThailandClinical34 (59.6)15 (26.3)≥15 (55.6, 35.5--75.7)Cross-sectional Consecutive57 (43)Sputum(57)Liquid media DST71Rachow A \[[@CR85]\]2011TanzaniaClinical141 (48.3)172 (58.9)Median 39.2Unspecified Consecutive292 (61)Sputum (292)Liquid media DST72Rahman A \[[@CR86]\]2016BangladeshClinicalNRNRNRUnspecified Unspecified92 (92)Sputum (92)Liquid media DST73Raizada N \[[@CR87]\]2014IndiaClinical2339 (50.8)NRChildren\< 14Prospective Consecutive4600 (48)Sputum (4600)DST74Reither K \[[@CR88]\]2015Tanzania UgandaClinical219 (45.6)197 (43.7)Children\< 16 (5.6, 2.0--9.8)Prospective Consecutive451 (25)Sputum (451)Liquid media DST75Rice JP \[[@CR89]\]2017AmericaLaboratoryNRNRMedian 50, IQR 35--60Retrospective Unspecified637 (120)Sputum (120)Liquid media DST76Sharma SK \[[@CR90]\]2015IndiaLaboratory909 (64.7)NRMedian 37.5, IQR 19.4--55.6Unspecified Consecutive1406 (422)Respiratory specimens (422)Solid and liquid media DST77Sharma SK \[[@CR91]\]2017IndiaLaboratory1405 (55.6)NRMedian 35.29, IQR 20--50Unspecified Convenient2468 (328)Extra-pulmonary specimens (328)Liquid media DST78Singh UB \[[@CR92]\]2016IndiaClinical589 (51.4)NRNRProspective Unspecified1145 (72)Pulmonary and Extra-pulmonary specimens (132)Liquid media DST79Soeroto AY \[[@CR93]\]2019IndonesiaClinical193 (56.9)5 (1.5)Median 38.2, IQR 25.7--50.7Retrospective Unspecified339 (158)NR (158)DST80Ssengooba W \[[@CR94]\]2014UgandaClinical155 (36.6)424 (100)Median 32, IQR 32--34Prospective Unspecified424 (9)Sputum (424)Liquid media DST81Strydom K \[[@CR95]\]2015South AfricaLaboratoryNRNRNRRetrospective Consecutive120 (115)Sputum (120)Liquid media DST82Tahseen S \[[@CR96]\]2016PakistanClinical1078 (54.3)NRMedian 33Cross-sectional Consecutive1984 (1533)Sputum (1533)Solid media DST83Theron G \[[@CR97]\]2011South AfricaClinical325 (67.7)130 (27.1)Adults≥18 (36, 18--83)Unspecified Consecutive480 (157)Sputum (480)Liquid media DST84Tsuyuguchi K \[[@CR98]\]2017JapanClinical146 (61.6)NRMedian 65.2, IQR 23--94Prospective Consecutive237 (201)Sputum (201)Solid media DST85Ullah I \[[@CR99]\]2017PakistanClinical130 (48.9)0 (0)Median 34, IQR 3--80Unspecified Unspecified266 (88)Extra-pulmonary specimens (88)DST86Vadwai V \[[@CR100]\]2011IndiaClinical251 (45.9)16 (2.9)Median 37, IQR 8 months-94Unspecified Consecutive547 (125)Biopsy (284), pus (147), body fluids (93), CSF (23)Solid and liquid media DST87van Kampen SC \[[@CR101]\]2015KazakhstanLaboratoryNR52(0.9)NRProspective Consecutive5611 (1054)Sputum (5611)Solid or liquid media DST88van Kampen SC \[[@CR102]\]2015IndonesiaClinical872 (60.5), missing 15(1.0)35 (2.4)0.5% \< 15, 97.7% ≥ 16, 1.8% missingUnspecified Consecutive1442 (339)Sputum (1442)DST89Wang G \[[@CR103]\]2017ChinaClinicalNRNRNRProspective Undefined1461 (538)Pulmonary specimens (1063), extra-pulmonary specimens (398)Solid media DST90Wang G \[[@CR104]\]2019ChinaClinical192 (65.75)0 (0)Median 42, IQR 14--89Prospective Consecutive292 (119)Sputum (90), pleural fluid (29)Solid or liquid media DST91Williamson DA \[[@CR105]\]2012New ZealandClinicalNRNRNRUnspecified Unspecified169 (14)Respiratory specimens (89); extra-pulmonary specimens (9), MGIT liquid culture vials (71)Liquid media DST92Yin QQ \[[@CR106]\]2014ChinaClinical141 (55.3)NRChildren≤18 (6.1, 0.3--15.3)Unspecified Unspecified255 (21)BALF (255)Liquid media DST93Yuan M \[[@CR107]\]2016ChinaClinicalNR0 (0)NRRetrospective Unspecified328 (90)Extra-pulmonary specimens (90)DST94Zar HJ \[[@CR108]\]2012South AfricaClinical294 (55.0)117 (21.9)Children\< 15 (19.0 months, 11.2--38.3 months)Unspecified Consecutive535 (125)Nasopharyngeal specimens, sputum (535)Liquid culture95Zar HJ \[[@CR109]\]2014South AfricaClinical181 (47)31 (8)Children\< 15 (38.3 months, 21.2--56.5 months)Prospective Consecutive384 (18)Sputum (309), Nasopharyngeal aspirate specimens (309)DST96Zetola NM \[[@CR110]\]2014BotswanaClinical221 (59.7)279 (59.4)Adult≥18 (37, 31--44)Retrospective Consecutive370 (370)Sputum (370)DST97Zhang AM \[[@CR111]\]2016ChinaClinical65 (59.6)0 (0)Children≤14Unspecified Unspecified109 (21)Pulmonary and Extra-pulmonary specimens (21)Liquid media DSTSample selection: Study units selected prospectively, or retrospectively from existing samples; Consecutive, random or convenience sampling method. 'Unspecified' refers to studies where there was no clear indication how the study participants were chosen. Solid media culture(Löwensten-Jensen), liquid media culture (Bactec MGIT 960)Table 2Data of diagnostic accuracy of studies included in the meta-analysis for rifampicin resistance tuberculosis detectionStudyFirst author \[ref.\]YearTotal samples n (included n)True positiveFalse positiveFalse negativeTrue negativeSpecimen typeStudyAl-Ateah SM \[[@CR15]\]2012234 (59)20057Respiratory and non-respiratory specimens1Antonenka U \[[@CR16]\]2013121 (50)20048Respiratory specimens2Balcells ME \[[@CR17]\]2012160 (12)02010Sputum3Barmankulova A \[[@CR18]\]2015300 (191)918389Sputum4Barnard M \[[@CR19]\]2012282 (36)30033Sputum5Bates M \[[@CR20]\]2013930 (41)21038Sputum, gastric lavage aspirate6Biadglegne F \[[@CR21]\]2014231 (32)21029Lymph node aspirates7Blakemore R \[[@CR22]\]2010168 (79)370042Sputum8Boehme CC \[[@CR23]\]20101730 (720)200105505Sputum9Peru341 (209)1630190Azerbaijan353 (143)474290South Africa726 (183)1801164India310 (185)1193261Boehme CC \[[@CR24]\]20116648 (1060)2361414796Sputum10Peru1185 (185)2211161Azerbaijan749 (211)4713160South Africa2522 (188)931175Uganda372 (116)112112India902 (103)82291Philippines918 (257)1496597Bowles EC \[[@CR25]\]201189 (60)80052Sputum, pleural fluid, gastric fluid, bronchial washing11Carriquiry G \[[@CR26]\]2012131 (39)63030Sputum12Cayci YT \[[@CR27]\]201734 (34)31030Respiratory and none-respiratory specimens13Chakravorty S \[[@CR28]\]2017139 (139)381397Sputum14Chiang TY \[[@CR29]\]20182957 (697)3690652Sputum15Chikaonda T \[[@CR30]\]2017351(200)210185Sputum16Ciftçi IH \[[@CR31]\]201185 (24)00024Sputum, BAL, thorasynthesis fluid, urine17Deggim V \[[@CR32]\]201379 (10)0307Respiratory and None-respiratory18Dharan NJ \[[@CR33]\]2016544 (185)859289Sputum19Dorman SE \[[@CR34]\]20126893 (144)550134Sputum20Dorman SE \[[@CR35]\]20181753 (551)16778369Sputum21Du J \[[@CR36]\]2015126 (43)92131Pleural biopsy specimen22Feliciano CS \[[@CR37]\]201829 (29)123410NR23Giang do C \[[@CR38]\]2015150(29)10028Respiratory and non-respiratory specimens24Gu Y \[[@CR39]\]201560 (24)60018Pus specimens25Guenaoui K \[[@CR40]\]201650 (50)210029Sputum26Helb D \[[@CR41]\] Uganda201064 (64)91054Sputum27Hillemann D \[[@CR42]\]2011521 (29)04025Non-respiratory specimens28Huang H \[[@CR43]\]20182910 (1066)147165898NR29Huh HJ \[[@CR44]\]2014300 (98)61190Respiratory specimens30Hu P \[[@CR45]\]20141352 (332)2642300Sputum31Jin YH \[[@CR46]\]2017109 (48)44139Pus32Kawkitinarong K \[[@CR47]\]2017521 (228)1501212Pulmonary specimens33Khalil KF \[[@CR48]\]201593 (93)50187BAL34Kim CH \[[@CR49]\]2014171 (26)20024Respiratory and non-respiratory specimens35Kim CH \[[@CR50]\]2015383 (36)41031Respiratory and Non Respiratory specimens36Kim MJ \[[@CR51]\]201552 (45)10143Respiratory and non-respiratory specimens37Kim SY \[[@CR52]\]201271 (62)210041Sputum38Kim YW \[[@CR53]\]20151429 (47)40142Non-respiratory specimens39Kim YW \[[@CR54]\]2015321 (321)2540292Sputum40Kokuto H \[[@CR55]\]201593 (56)40250Fecal specimens41Kostera J \[[@CR56]\]2018132 (122)280490Sputum42Kurbaniyazova G \[[@CR57]\]20172734 (364, solid media DST)1202012212NR2734 (414, liquid media DST)1082913264NR43Kurbatova EV \[[@CR58]\]2013201 (99)571536Sputum44Kwak N \[[@CR59]\]2013681 (127)860113Sputum45Lawn SD \[[@CR60]\]2011468 (55)43048Sputum46Lee HY \[[@CR61]\]2013132 (35)20033Bronchoscopy specimens47Li Q \[[@CR62]\]20161973 (449)47166380Sputum48Li Y \[[@CR63]\]2017420 (59)110147Extra-pulmonary specimens49Liu X \[[@CR64]\]2015134 (44)102131Pleural biopsy and pleural fluid specimens50Lorent N \[[@CR65]\]2015299 (102)246369Sputum51Luetkemeyer AF \[[@CR66]\]2016992 (194)512186Sputum52Metcalfe JZ \[[@CR67]\]2016352 (161)548990Sputum53Mokaddas E \[[@CR68]\]2015452 (452)1020440Respiratory and non-respiratory specimenssmear(+)(179)400175smear(−)(273)620265pulmonary(287)710279extrapulmonary(165)31016154Moon HW \[[@CR69]\]2015100 (100)470350Respiratory specimens55Muñoz L \[[@CR70]\]2011122 (85)60178Respiratory and non-respiratory specimens56Mwanza W \[[@CR71]\]20181070 (24)13308NR57Myneedu VP \[[@CR72]\]2014134 (88)541132Sputum58N'guessan K \[[@CR73]\]2014120 (29)144011Sputum59N'Guessan K \[[@CR74]\]20181095 (162)1128042Sputum60Nikolayevskyy V \[[@CR75]\]20183478 (3167)121277861792Pulmonary specimens61Nicol MP \[[@CR76]\]2011452 (77)34070Sputum62O'Grady J \[[@CR77]\]2012881 (96)132378Sputum63Ou X \[[@CR78]\]20142454 (616)54168538Sputum64Ozkutuk N \[[@CR79]\]20142639 (133)110131Respiratory and non-respiratory specimens65Pan X \[[@CR80]\]2018190 (62)22058Sputum and BAL66Pang Y \[[@CR81]\]2014211 (10)1009Gastric lavage aspirates67Park KS \[[@CR82]\]2013320 (19)20017Respiratory specimens68Pimkina E \[[@CR83]\]2015791 (264)3940221Sputum69Pinyopornpanish K \[[@CR84]\]201557 (43)00340Sputum70Rachow A \[[@CR85]\]2011292 (61)00061Sputum71Rahman A \[[@CR86]\]201692 (92)85601Sputum72Raizada N \[[@CR87]\]20144600 (48)47100Sputum73Reither K \[[@CR88]\]2015451 (25)00025Sputum74Rice JP \[[@CR89]\]2017637 (120)220116Sputum75Sharma SK \[[@CR90]\]20151406 (422)10476305Respiratory specimens76Sharma SK \[[@CR91]\]20172468 (328)3823285Extra-pulmonary specimens77Singh UB \[[@CR92]\]20161145 (72)140256Pulmonary and extra-pulmonary specimens78Soeroto AY \[[@CR93]\]2019339 (158)1411700NR79Ssengooba W \[[@CR94]\]2014424 (94)4009Sputum80Strydom K \[[@CR95]\]2015120 (115)591253Sputum81Tahseen S \[[@CR96]\]20161984 (1533)8517151416Sputum82Theron G \[[@CR97]\]2011480 (157)510151Sputum83Tsuyuguchi K \[[@CR98]\]2017237 (201)2230176Sputum84Ullah I \[[@CR99]\]2017266 (88)242062Extra-pulmonary specimens85Vadwai V \[[@CR100]\]2011547 (125)395180Non-respiratory specimens86van Kampen SC \[[@CR101]\]20155611(1054)5223133468Sputum87van Kampen SC \[[@CR102]\]20151442 (339)1581821142Sputum88Wang G \[[@CR103]\]20171461 (538)14503390Pulmonary and extra-pulmonary specimens89Wang G 104\]2019229 (119)210197Sputum, pleural fluid90150174Sputum2960023Pleural fluid90Williamson DA \[[@CR105]\]2012169 (14)7601Respiratory; extra-pulmonary specimens, positive MGIT liquid culture vials91Yin QQ \[[@CR106]\]2014255 (21)10020BALF92Yuan M \[[@CR107]\]2016328(90)120375Extra-pulmonary specimens93Zar HJ \[[@CR108]\]2012535 (125)551114Nasopharyngeal specimens, sputum94Zar HJ \[[@CR109]\]2014384 (18)00018Sputum Nasopharyngeal aspirate specimens95Zetola NM \[[@CR110]\]2014370 (370)5114314Sputum97Zhang AM \[[@CR111]\]2016109 (21)60015Pulmonary and extra-pulmonary specimens*IQR* Interquartile range, *TA* Tracheal aspirate, *BA* Bronchial aspirate, *BAL* Bronchoalveolar lavage, *LN* Lymph node, *CSF* Cerebrospinal fluid, *EPTB* Extra-pulmonary tuberculosis, *CCRS* Composite clinical reference standard, *FNA* Fine needle aspirate; DST: drug-susceptibility testing

Methodological quality of included studies {#Sec10}
------------------------------------------

The overall methodological quality of the included studies was summarized in Fig. [2](#Fig2){ref-type="fig"}. Approximately half of the included studies collected data consecutively (*n* = 41; 42.2%) (Table [1](#Tab1){ref-type="table"}) and no study used a case-control design. All studies were carried out either in tertiary care centers or reference laboratories. In index tests part, 15 studies (15.5%) were considered as unclear risk of bias. In reference standard part, 11 studies (11.3%) were considered as unclear risk of bias because the results of the reference standard were interpreted with unclear blind of the results of the index tests. In flow and timing part, 14 studies (24.7%) were considered as unclear risk of bias because not all patients were included in the analysis.Fig. 2Risk of bias and applicability concerns as percentages across the included studies for rifampicin resistance detection

The heterogeneity of the studies included in this study was tested by a bivariate boxplot (Fig. [3](#Fig3){ref-type="fig"}a) and a Deek's funnel plot (Fig. [3](#Fig3){ref-type="fig"}b). Most of the included studies were in the bivariate boxplot, and the slope of Deek's funnel was almost horizontal, which all meant a good heterogeneity.Fig. 3Heterogeneity test of included studies in this meta-analysis: a bivariate boxplot (**a**) and a Deek's funnel plot (**b**)

Detection of rifampicin resistance in different prevalence and income regions {#Sec11}
-----------------------------------------------------------------------------

The accuracy of Xpert MTB/RIF for rifampicin resistance detection was estimated in 59 studies. The pooled sensitivity, specificity and AUC of Xpert MTB/RIF for detecting rifampicin resistance were 0.93 (95% CI 0.90--0.95), 0.98 (95% CI 0.96--0.98) and 0.99 (95% CI 0.97--0.99), respectively (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4The SROC plot of Xpert MTB/RIF sensitivity and specificity for rifampicin resistance detection. The points represent the sensitivity and specificity of one study; the summary point represents the summary sensitivity and specificity

Of the 97 studies, 26 studies were of high income countries, 62 of middle and 9 were of low income. For TB prevalence, 52 studies were from the 22 high TB burden countries, and 45 were not. The pooled sensitivity were 0.94(95% CI 0.89--0.97) and 0.92 (95% CI 0.88--0.94), the pooled specificity were 0.98 (95% CI 0.94--1.00) and 0.98 (95% CI 0.96--0.99), and the AUC were 0.99 (95% CI 0.98--1.00) and 0.99 (95% CI 0.97--0.99) in high and middle/low income countries, respectively (Fig. [5](#Fig5){ref-type="fig"}a and Fig. [5](#Fig5){ref-type="fig"}b). The pooled sensitivity were 0.91 (95% CI 0.87--0.94) and 0.91 (95% CI 0.86--0.94), the pooled specificity were 0.98 (95% CI 0.96--0.99) and 0.98 (95% CI 0.96--0.99), and the AUC were 0.98 (95% CI 0.97--0.99) and 0.99 (95% CI 0.97--0.99) in high TB burden and middle/low prevalence countries, respectively (Fig. [5](#Fig5){ref-type="fig"}c and Fig. [5](#Fig5){ref-type="fig"}d).Fig. 5The SROC plot of Xpert MTB/RIF sensitivity and specificity for rifampicin resistance detection. **a** High income countries, **b** Middle/low income countries, **c** High TB burden countries, **d** Middle/low TB prevalence countries. The points represent the sensitivity and specificity of one study; the summary point represents the summary sensitivity and specificity

Discussion {#Sec12}
==========

Several meta-analyses have focused on the diagnostic accuracy of Xpert MTB/RIF for pulmonary \[[@CR12]\] or extra-pulmonary TB \[[@CR13], [@CR14]\] detection either on adults or children \[[@CR12]\]. However, to our knowledge, this is the first meta-analysis for Xpert MTB/RIF diagnostic accuracy for rifampicin resistance detection in different prevalence and income regions. Our systematic review demonstrated that Xpert MTB/RIF is high sensitive diagnostic tool for rifampicin resistance detection. Firstly, the accuracy of Xpert MTB/RIF for rifampicin resistance detection was estimated in our meta-analysis. As shown in Fig. [4](#Fig4){ref-type="fig"}, the accuracy of Xpert MTB/RIF for rifampicin resistance detection was impressive. The pooled sensitivity, specificity and AUC were 0.93 (95% CI 0.90--0.95), 0.98 (95% CI 0.96--0.98) and 0.99 (95% CI 0.97--0.99), respectively. As estimated, about 75% of multi-drug resistant TB remains undiagnosed \[[@CR4]\]. We strongly hope Xpert MTB/RIF, which provided a quick and accurate result, will contribute to early and accurate diagnosis of rifampicin resistance.

The overall sensitivity of Xpert MTB/RIF for rifampicin resistance detection were almost the same between high TB prevalence countries and middle/low ones (0.91, 95% CI 0.87--0.94 versus 0.91, 95% CI 0.86--0.94). And for different income levels, the sensitivities of high income ones was also similar with the ones of middle/low income (0.94, 95% CI 0.89--0.97 versus 0.92, 95% CI 0.88--0.94). We can see, taking the different levels of TB prevalence and country income into account, no significant differences were found between subgroups, either in sensitivities, specificities and AUCs.

TB remains one of the world's deadliest communicable diseases. However, it is intensively distributed in several high burden countries. In 2017, more than half of the new TB was developed in the South-East Asia and Western Pacific Regions. To be specific, one quarter were in the African Region. India and China alone accounted for 24 and 13% of the total cases, respectively \[[@CR4]\]. Interestingly, the tendency of TB prevalence was consisted with the economic development at some degree. The income levels of the 22 high TB burden countries all were all middle or low, except one (Russian) \[[@CR4]\]. Therefore, it is of significant meanings to estimate the diagnostic accuracy of Xpert MTB/RIF in countries with different levels of TB prevalence and income. Some researchers discovered that the Xpert MTB/RIF showed a higher sensitivity of TB detection in lower TB prevalence countries, which could significantly help the physicians to make clinical decisions \[[@CR112]\]. However, our result, from another aspect, showed the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance detection was not differed between countries with different TB prevalence and incomes.

Advantages of this review were the use of a standard protocol, a bivariate random-effects model used for meta-analysis, and independent reviewers. The data set involved comprehensive searching to identify studies as well as repeated correspondence with authors of study to obtain additional data on the studies.

While there were still some limitations in our analysis. We may have missed some studies despite the comprehensive search. Secondly, sample processing was highly variable across and within studies, as there was no recommendation available on how to process non-respiratory samples from the manufacturer or the WHO.

Conclusions {#Sec13}
===========

In conclusion, based on our meta-analysis, the diagnostic accuracy of Xpert MTB/RIF for rifampicin resistance detection was excellent. The overall sensitivity of Xpert MTB/RIF for rifampicin resistance detection in different TB prevalence and income countries were not significant different. We believe that the information obtained from this study will aid the decision making of physicians who take care of patients with possible resistant tuberculosis infection.
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